According to a stratification procedure, the objective of a personalised care plan (VitalCare) is to identify points for improvement since the early stage of the patient's pathway of CPAP/APAP treatment and to adjust patient follow-up .
It is a prospective, exploratory, randomised, multi-centre, open, controlled study with a 1:1 ratio of two parallel groups, with obstructive sleep apnoea patients starting CPAP/APAP therapy, and receiving by the homecare provider, either an individualised treatment plan (VitalCare) or national standard of care. This study will be conducted in 5 hospital centres in Portugal.. During a regular medical consultation, eligible patients who have signed their informed consent will be randomised by their investigator. Two study groups will be set up: 1. Standard of care group 2. VitalCare group Two medical visits in the hospital centres will be scheduled in the context of the study for all participating patients: 1. A screening/inclusion visit before CPAP/APAP initiation at home; 2. An end-of-study visit planned at 12 months (± 1 month) after CPAP/APAP initiation at home. All visits done in the hospital centres at the discretion of the investigators between patient's screening/inclusion visit and end-of-study visit will be recorded in the eCRF with the reason for the visit and change in CPAP/APAP prescription, if applicable The primary objective of this study is to evaluate adherence to CPAP/APAP treatment at 3 months in patients with individualised treatment plan (VitalCare) compared to patients with standard of care
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
113
VitalCare is a treatment plan to help in the personalisation of patient care.
Hospital Distrital de Santarém
Santarém, Portugal
CPAP/APAP adherence evaluation
average daily number of hours of CPAP/APAP use at 3 months
Time frame: 3rd month
adherence to CPAP/APAP
daily average duration of CPAP/APAP use
Time frame: 1st, 6th,12th months
evolution of daily Apnoea-Hypopnoea Index (AHI) and Non intentional leaks level teletransmitted by CPAP/APAP devices
Daily Apnoea-Hypopnoea Index (AHI) expressed in average daily number per hour and daily non intentional leaks level expressed in L/min as both median and 95th percentile
Time frame: 1st, 3rd, 6th,12th months
daytime sleepiness
The numerical answers obtained for the 8 common daily life situations of the Epworth Sleepiness Scale (ESS) are added to calculate the ESS score each time it is collected
Time frame: 1st, 3rd, 6th,12th months
Snoring and Quality of Life
The numerical answers obtained for the 5 questions of the snoring questionnaire are added to calculate the snoring score each time the questionnaire is collected. The numerical answer from 0 to 10 obtained on the Quality of Life visual analogue scale is used each time the questionnaire is collected.
Time frame: 1st, 3rd, 6th,12th months
For patients in the VitalCare group, Balachandran CPAP perception questionnaire
The numerical answers obtained for the 4 questions regarding difficulty tolerating CPAP, discomfort with CPAP pressure, likelihood of wearing CPAP, and perceived health benefit are added to calculate the CPAP perception score each time it is collected.
Time frame: 1st, 3rd, 6th,12th months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of contacts between home healthcare provider and patient
The data files extracted from the home healthcare provider database will allow to count for each study patient, the number of contacts between the home healthcare provider and the patient either i) at home, ii) remotely or iii) in care centres
Time frame: 1st, 3rd, 6th,12th months
For patients in the VitalCare group, number of updates of the individualised treatment plan
The data files extracted from the home healthcare provider database will allow to count for each patient from the VitalCare group, the number of updates of the individualised treatment plan
Time frame: 1st, 3rd, 6th,12th months
adverse events description
all adverse events recorded by investigators in the eCRF
Time frame: through study completion, an average of 1 year